Cargando…
Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42)
For decades, a link between increased levels of iron and areas of Alzheimer's disease (AD) pathology has been recognized, including AD lesions comprised of the peptide β-amyloid (Aβ). Despite many observations of this association, the relationship between Aβ and iron is poorly understood. Using...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006257/ https://www.ncbi.nlm.nih.gov/pubmed/24671940 http://dx.doi.org/10.1098/rsif.2014.0165 |
_version_ | 1782314205136814080 |
---|---|
author | Everett, J. Céspedes, E. Shelford, L. R. Exley, C. Collingwood, J. F. Dobson, J. van der Laan, G. Jenkins, C. A. Arenholz, E. Telling, N. D. |
author_facet | Everett, J. Céspedes, E. Shelford, L. R. Exley, C. Collingwood, J. F. Dobson, J. van der Laan, G. Jenkins, C. A. Arenholz, E. Telling, N. D. |
author_sort | Everett, J. |
collection | PubMed |
description | For decades, a link between increased levels of iron and areas of Alzheimer's disease (AD) pathology has been recognized, including AD lesions comprised of the peptide β-amyloid (Aβ). Despite many observations of this association, the relationship between Aβ and iron is poorly understood. Using X-ray microspectroscopy, X-ray absorption spectroscopy, electron microscopy and spectrophotometric iron(II) quantification techniques, we examine the interaction between Aβ(1–42) and synthetic iron(III), reminiscent of ferric iron stores in the brain. We report Aβ to be capable of accumulating iron(III) within amyloid aggregates, with this process resulting in Aβ-mediated reduction of iron(III) to a redox-active iron(II) phase. Additionally, we show that the presence of aluminium increases the reductive capacity of Aβ, enabling the redox cycling of the iron. These results demonstrate the ability of Aβ to accumulate iron, offering an explanation for previously observed local increases in iron concentration associated with AD lesions. Furthermore, the ability of iron to form redox-active iron phases from ferric precursors provides an origin both for the redox-active iron previously witnessed in AD tissue, and the increased levels of oxidative stress characteristic of AD. These interactions between Aβ and iron deliver valuable insights into the process of AD progression, which may ultimately provide targets for disease therapies. |
format | Online Article Text |
id | pubmed-4006257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The Royal Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-40062572014-06-06 Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42) Everett, J. Céspedes, E. Shelford, L. R. Exley, C. Collingwood, J. F. Dobson, J. van der Laan, G. Jenkins, C. A. Arenholz, E. Telling, N. D. J R Soc Interface Research Articles For decades, a link between increased levels of iron and areas of Alzheimer's disease (AD) pathology has been recognized, including AD lesions comprised of the peptide β-amyloid (Aβ). Despite many observations of this association, the relationship between Aβ and iron is poorly understood. Using X-ray microspectroscopy, X-ray absorption spectroscopy, electron microscopy and spectrophotometric iron(II) quantification techniques, we examine the interaction between Aβ(1–42) and synthetic iron(III), reminiscent of ferric iron stores in the brain. We report Aβ to be capable of accumulating iron(III) within amyloid aggregates, with this process resulting in Aβ-mediated reduction of iron(III) to a redox-active iron(II) phase. Additionally, we show that the presence of aluminium increases the reductive capacity of Aβ, enabling the redox cycling of the iron. These results demonstrate the ability of Aβ to accumulate iron, offering an explanation for previously observed local increases in iron concentration associated with AD lesions. Furthermore, the ability of iron to form redox-active iron phases from ferric precursors provides an origin both for the redox-active iron previously witnessed in AD tissue, and the increased levels of oxidative stress characteristic of AD. These interactions between Aβ and iron deliver valuable insights into the process of AD progression, which may ultimately provide targets for disease therapies. The Royal Society 2014-06-06 /pmc/articles/PMC4006257/ /pubmed/24671940 http://dx.doi.org/10.1098/rsif.2014.0165 Text en http://creativecommons.org/licenses/by/3.0/ © 2014 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original author and source are credited. |
spellingShingle | Research Articles Everett, J. Céspedes, E. Shelford, L. R. Exley, C. Collingwood, J. F. Dobson, J. van der Laan, G. Jenkins, C. A. Arenholz, E. Telling, N. D. Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42) |
title | Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42) |
title_full | Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42) |
title_fullStr | Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42) |
title_full_unstemmed | Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42) |
title_short | Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42) |
title_sort | ferrous iron formation following the co-aggregation of ferric iron and the alzheimer's disease peptide β-amyloid (1–42) |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006257/ https://www.ncbi.nlm.nih.gov/pubmed/24671940 http://dx.doi.org/10.1098/rsif.2014.0165 |
work_keys_str_mv | AT everettj ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT cespedese ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT shelfordlr ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT exleyc ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT collingwoodjf ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT dobsonj ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT vanderlaang ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT jenkinsca ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT arenholze ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 AT tellingnd ferrousironformationfollowingthecoaggregationofferricironandthealzheimersdiseasepeptidebamyloid142 |